ScripsAmerica Inc. (SCRCQ)

[Danna]

ScripsAmerica's RapiMed(R)$SCRC Product Generates Tremendous Retail Interest at the 2013 ECRM Cough/Cold, Analgesics & Allergy Conference

http://www.reuters.com/article/2013/02/27/idUSnGNXUXFYRa+1fe+GNW20130227


NEW CASTLE, Del., Feb. 27, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC), a leading
supplier of prescription, OTC and nutraceutical drugs, today announced that the Company's RapiMed®
http://www.globenewswire.com/newsroom/ctr?d=10023044&l=1&a=RapiMed%C2%AE&u=http%3A%2F%2Fwww.rapimeds.com%2F
line of children's pain and fever reliever was extremely well received at the 2013 "Cough/Cold,
Analgesics & Allergy EPPS" conference which was held in Destin, Florida from February 17 - 21st.

The annual conference, sponsored by Efficient Collaborative Retail Marketing (ECRM), brings
together makers of cough and cold, allergy, analgesics, vaporizers, humidifiers, and digestive
branded and private label suppliers to present new programs to North America's top retailers
across all channels. ScripsAmerica presented RapiMed to promote its placement and sale across
retail outlets throughout the United States and reports that the Company received verbal order
commitments from 62 of 66 retailers that it met with during the conference.

ScripsAmerica's RapiMed line of orally dissolving pediatric pain and fever relievers seeks to beat
McNeil Consumer Healthcare's Tylenol Meltaways' return to the market and win market share over
private label manufacturers by promising to melt faster, taste better and be smaller than
competing products. RapiMed also addresses FDA dosing concerns and will target the nation's
rapidly growing Hispanic consumer population with labeling in both English and Spanish, which the
Company believes will contribute to its competitive advantage.

"ScripsAmerica is pleased to report that our RapiMed pediatric product was received exceptionally
well by retail chains from across the nation at this year's ECRM show. The extremely high number
of verbal commitments for product orders we received at the show increases our confidence that
RapiMed will be widely embraced by consumers shopping for a pediatric pain and fever reliever due
to its ability to melt faster, taste better and be more accurately dosed than the competing
products," commented CEO of ScripsAmerica, Bob Schneiderman.